

## Fully Automated Simultaneous Analysis of Cephem Antibiotics in Serum by LC-MS/MS

Kohei Yoshikawa and Toshikazu Minohata

### User Benefits

- ◆ Simultaneous analysis of 12 different cephem antibiotics is possible.
- ◆ The entire process is automated, from biological sample preparation to LC-MS/MS measurement.
- ◆ Good reproducibility is achieved with a measurement cycle time of 7 minutes.

### Introduction

Cephem antibiotics like penicillin and carbapenems are a type of  $\beta$ -lactam antibiotic used in oral medicines and injectable solutions. Cephem antibiotics are said to be effective for various illnesses because they have a high safety profile with a low frequency and degree of side effects.

Here, we introduce a simultaneous analysis method for cephem antibiotics in blood plasma by LC-MS/MS using the CLAM-2030, which enables fully-automated pretreatment of biological samples. The CLAM-2030 can be used to reduce specimen mix-ups and variations in procedure.

There are 50 main cephem antibiotics, of which 12 components (cefadroxil, cefapirin, cefaclor, cephalexin, cefuroxime, cefotaxime, cefoxitin, cefazolin, cepharazine, cefoperazone, cefamandole, and cephalothin) were targeted in this analysis system.



Fig. 1 LC-MS/MS System with Fully Automated Pretreatment System




Fig. 2 Flow Diagram (Trap & Elute System)

### Analytical Condition

The LC/MS system consisting of a CLAM-2030 fully-automated LCMS pretreatment instrument, a Nexera™ X2 ultra-high performance liquid chromatograph, and an LCMS-8060 triple quadrupole mass spectrometer was used (Fig. 1).

Table 1 shows the HPLC and MS analysis conditions. The trap column, analytical column, and mobile phase included in the DOSIMMUNE™ immunosuppressant analysis kit were used: the sample injected into LC-MS/MS is concentrated and purified by the trap column then separated by the analytical column (Fig. 2). The three stable isotope-labeled compounds used as internal standards (IS) were from Alsachim.

Table 1 Analytical Condition

HPLC Conditions	
Column:	Nexera X2 DOSIMMUNE trapping column DOSIMMUNE analytical column
Mobile Phases:	DOSIMMUNE mobile phase A, B
Flowrate:	A/B 0.5 mL/min (for analysis) C 1.2 mL/min (for trap)
Time Program:	1 %B(0-0.5 min) – 30 %B(3 min) – 98 %B(4-5 min) – 1 %B(5.01-7 min)
Column Temp.:	40 °C
Injection Volume:	1 $\mu$ L
MS Conditions	
Ionization:	LCMS-8060 ESI-positive
Nebulizing Gas Flow:	3 L/min
Drying Gas Flow:	10 L/min
Heating Gas Flow:	10 L/min
Interface Temp.:	300 °C
DL Temp.:	200 °C
Heat Block Temp.:	400 °C
Mode:	MRM

Analyte	MRM	R.T (min)
Cefadroxil	364.00 > 114.05	1.221
Cefapirin	424.00 > 292.05	1.812
Cefaclor	368.00 > 174.10	1.957
Cephalexin	348.00 > 158.10	2.047
Cefuroxime	442.00*2 > 364.05	2.176
Cefotaxime	456.00 > 125.05	2.284
Cefoxitin	445.00*2 > 215.10	2.297
Cefazolin	455.00 > 323.10	2.315
Cephadrine	350.00 > 176.15	2.320
Cefoperazone	646.00 > 143.15	2.939
Cefamandole	463.00 > 158.05	3.110
Cephalothin	414.00*2 > 152.00	3.520
[2H5]-Cefaclor (C7546)*1	373.00 > 179.15	1.941
[2H5]-Cephalexin (C6695)*1	353.00 > 158.05	2.032
[13C,2H3]-Cefotaxime (C6106)*1	460.00 > 125.05	2.269

\*1 Product Number of Alsachim

\*2 [M+NH4]<sup>+</sup>

### ■ Analysis of Cephem Antibiotic Standards

Six calibrators were prepared for 12 cephem antibiotics at 0.01, 0.05, 0.1, 0.5, 1, and 5 µg/mL. They were analyzed six times for each point, and the results are shown in Fig. 3 and Fig. 4.

Good linearity with an R2 value of 0.998 or higher for each compound was obtained over the calibrator's concentration range. The accuracy of each calibration point was also within  $100 \pm 10\%$  for each compound, and the area value reproducibility (%RSD) was better than 15%.




Fig. 3 Calibration Curves for 12 Cephem Antibiotics




Fig. 4 MRM Chromatograms of 12 Cephem Antibiotics at the Lower Limit of the Calibration

## ■ Analysis of Cephem Antibiotics in Plasma Samples by CLAM-2030

Samples were prepared with 12 cephem antibiotics added to plasma at 0.3 and 3 µg/mL, and the internal standard was prepared to 5 µg/mL each.

The pretreatment process of the plasma samples in the CLAM-2030 is shown in Fig. 5. First, 20 µL of 75 % isopropanol was added, then 20 µL of plasma sample, 10 µL of IS, and 100 µL of methanol were added and stirred, followed by suction filtration and LC-MS/MS analysis.

The results of the assay with two concentrations of plasma samples are shown in Table 2. Pretreatment dilutes the cephem antibiotics in the plasma samples to 20/150, resulting in final concentrations of 0.04 and 0.4 µg/mL in the measured samples, respectively. The accuracy was within 100 ± 15 % for each compound, and the reproducibility of concentration values (%RSD) was better than 15 %.




Fig. 5 Pretreatment Process with CLAM-2030

Table 2 Results of the Assay with Two Concentrations of Plasma Samples

Conc. (µg/mL)	0.3 (Final conc. 0.04)			3 (Final conc. 0.4)		
	Measured value (µg/mL)	Accuracy%	%RSD	Measured value (µg/mL)	Accuracy%	%RSD
<b>Cefaclor</b>	0.28	92.4	12.1	2.89	96.3	1.8
<b>Cefalexin</b>	0.30	100.4	5.0	3.14	104.5	5.3
<b>Cefotaxime</b>	0.27	89.8	2.5	2.87	95.5	3.5
<b>Cefazolin</b>	0.28	94.7	5.1	2.97	99.1	2.2
<b>Cefuroxime</b>	0.29	96.4	5.9	2.85	95.1	3.5
<b>Cefoperazone</b>	0.29	98.1	1.9	2.97	99.0	4.3
<b>Cefoxitin</b>	0.29	96.7	5.5	2.99	99.6	5.4
<b>Cefamandole</b>	0.29	97.2	2.6	3.02	100.6	6.4
<b>Cephadrine</b>	0.29	96.2	2.3	2.96	98.8	3.0
<b>Cephalothin</b>	0.28	93.6	2.3	2.95	98.4	4.7
<b>Cefapirin</b>	0.32	107.7	6.3	3.28	109.3	2.9
<b>Cefadroxil</b>	0.33	110.9	5.7	3.42	113.9	2.0

Nexera, CLAM, and DOSIMMUNE are trademarks of Shimadzu Corporation or its affiliated companies in Japan and/or other countries.



Shimadzu Corporation

www.shimadzu.com/an/

**For Research Use Only. Not for use in diagnostic procedures.**

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. See <http://www.shimadzu.com/about/trademarks/index.html> for details.

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®".

Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

01-00444-EN

First Edition: Mar. 2023